Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.

JSON

Di Giacomo AM, Simonelli M, Santangelo F, Amato G, Simonetti E, Graham J, Lahn MMF, Di Conza G, Hammett T, Zorrilla R, Durini M, Tan Z, Tadepally L, Brodin P, Occhipinti M, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans TRJ, Maio M

J Clin Oncol 42 (16_suppl) 9597-9597 [2024-06-01; online 2024-06-01]

DOI 10.1200/jco.2024.42.16_suppl.9597

Crossref 10.1200/jco.2024.42.16_suppl.9597